


GENERAL PHARMACOLOGY

CHAPTER

Pharmacology :- It is the science which deals with the study of drugs and its Mechanism ADR, contraindication and therapeutic uses etc



(1) Pharmacokinetic

Absorption- Primary site - small intestine (Basic PH-7.4)

other - stomach for acidic drug

◆ Drug may be acidic or basic get absorbed by ionization (Not 100 % or Not zero)

Ionisation

Ionised form
(water soluble)

un ionised form
(lipid soluble)

↓
can cross biological
membrane

↓
get absorbed

Bio availability (BA) - fraction or concentration reaches in blood circulation in unchanged form.


◆ Metabolic form not counted as bioavailable amount.

Bioavailability depends on:-

(1) BA \propto Absorption

(2) BA $\propto \frac{1}{\text{first pass metabolism}}$

(3) Route of Drug administration
◆ Systemic > Local route



- ◆ Parental > oral
- ◆ IV route have 100 %

2) **Distribution** - Amount of blood distributed drug into various tissue called volume of Distribution (Vd).

$$Vd = \frac{\text{Dose Administered I.V}}{\text{Plasma concentration}}$$

$$Vd \propto \text{Lipid Solubility}$$

$$Vd \propto \frac{1}{\text{Plasma protein Binding}}$$

- ◆ Min Vd should be 42 L/kg .
- ◆ Max Vd 1300 L/kg (chloroquine with highest Vd).
- ◆ Vd \propto Plasma Half life.
- ◆ Vd determine loading dose.

Metabolism

- ◆ Most of Drug are deactivated by metabolism.
- ◆ **Primary site** - liver (Max enzymatic concentration).
- ◆ **Other**- Lungs, Adipose tissue, small intestine etc.
- ◆ First pass metabolism may be in small intestine, lungs ,Adipose tissue and liver.
- ◆ Some drug get activated from its inactivated form called prodrug.
- ◆ Microsomal and Non microsomal enzyme are involved in meta bolism.
- ◆ Microsomal enzyme can be induced or inhibited by other drugs.

Enzyme inducer

1) **Enzyme inducer** \uparrow ese metabolism, \uparrow Elimination

\downarrow Effect of other drug

- ◆ So increase dose when administered with enzyme inducer
- Ex.** Griseofulvin, phenytoin, Rifampicin, smoking, carbamazepine, phenobarbitone
- ◆ Phenobarbitone and phenytoin are CI (contra indication) in porphyria because They \uparrow ese porphyrin

2) **Enzyme inhibitor** \downarrow ese metabolism, slow Elimination, Predispose toxicity

Ex - MAO inhibitor, valproate, ketoconazole, cimetidine, ciprofloxacin ,Erythromycin and INH.
Metronidazole, chloramphenicol etc.

3) **Prodrug** - Drug activated by metabolism .

- ◆ Biological effect related to active metabolite

Ex. ◆ All PPI

- ◆ All ACE inhibitor except captopril and lesinopril
- ◆ NSAID - Sulindac, Nebumetone
- Anticancer - cyclophosphamide, Mercaptopurin, fourouracil
- Anti influenza - Osaltamavir (Doc in swine flue and Bird flu)
- Dipivefrine - Doc in Iron poisoning during thalasemia treatment (orphan drug)
- Sulfonamide - sulfasalazine

Phase I (Non synthetic) reaction - Attachment of functional group

Ex.- oxidation, Reduction, Hydroxylation, cyclization and decyclization

- ◆ Drug after phase I reaction may be lipid soluble or water soluble

Phase II (synthetic) Attachment of conjugate

Ex. sulfation, methylation, acetylation, glucoronidation, glycine conjugation or other conjugation

- ◆ Drug after phase II reaction will be water soluble

Excretion**Primary site** - kidney

- Nephron is unit of excretion
- GFR - 130 ml/min

1) **Glomerular filtration** - depends on plasma protein Binding and renal Blood flow.

2) **Tubular reabsorption** - depend on lipid solubility

3) **Tubular secretion** - Neither depend on lipid solubility Nor on plasma protein Binding or Renal Blood flow

Rate of Elimination

◆ **Clearance** - Rate of Elimination divided by its plasma concentration

◆ **Order of kinetic:-**

Rate of Elimination \propto [Plasma concentration]^{order}

1) **first order kinetic** (Linear kinetic)

- ◆ Constant fraction of drug eliminated per unit time.
- ◆ Clearance - constant.
- ◆ Half life - constant.
- ◆ Max. drug follow first order kinetic.
- ◆ Rate of elimination depend on plasma concⁿ

2) **Zero order kinetic** (Non Linear kinetic)

- ◆ constant amount of drug eliminated per unit time

Clearance - At low concⁿ - clearance is more

At high concⁿ - clearance is less

Half life - At high concⁿ - $t_{1/2}$ is more

At low concⁿ - $t_{1/2}$ is less

- ◆ Always independent to plasma concⁿ

Ex- warferrin, Aspirin, Alcohol, Theophylline, Tolbutamide and phenytoin.

(2) Pharmacodynamic

- ◆ Effect of drug on body.
- ◆ Include Action and mechanism of drug.
- ◆ Both enzyme and receptor are involved

(i) Receptor:-

Affinity - Ability of drug bind or combine with receptor

Intrinsic Activity - Ability of drug to activate receptor also called Efficacy

- ◆ IA may be +1 to zero to +1
- ◆ Agonist \rightarrow IA = +1 (Maximal activation)
- ◆ Partial Agonist \rightarrow IA = zero to +1 (Submaximal activation)

- ◆ Antagonist → IA = zero
- ◆ Inverse Agonist → IA = -1

(ii) Enzyme inhibition

◆ Competitive Enzyme inhibition

- similar structure of drug and substrate
- Need active site to bind
- Inhibition can be overcome by increasing concⁿ of substrate

◆ Non competitive Enzyme inhibition

- No similar structure of drug and substrate
- No need of active site
- Inhibition can not overcome by increasing concentration dose of substrate

Half life

Time required to reduce plasma concentration to 50 % of the original value.

$$t_{1/2} = \frac{0.693 \times v_d}{\text{clearance}}$$

Half life depend on metabolism, v_d, and clearance.

Therapeutic Drug monitoring (TDM)

- ◆ Dose Adjustment according to plasma concⁿ
- ◆ More TI → drug safe
- ◆ Less TI (Therapeutic index) → drug may be toxic
- ◆ TDM done for drug those serum level and toxicity are correlated
- ◆ TDM required for Drugs having low therapeutic index (Digitalis, Lithium, TCA, Theophylline and teoclemus etc)
- ◆ TDM is not done for prodrug.

Receptor (Protein material)

1) GPCR (G protein coupled receptor) - α , β , Muscarinic 5HT₁, 5HT₂

2) Ionotropic - fastest acting receptor Ex. GABA_A, NM DA, 5HT₃, N_M, N_N

3) Enzymatic - Have two site (1) Extracellular - for drug (2) Intracellular - enzymatic (Tyrosine kinase)
Ex- Insulin, GH, Prolactin, cytokines

4) Intracellular - slowest acting

(a) Cytoplasmic - glucocorticoid, Mineralocorticoid and Vit-D

(b) Nuclear - T₃, T₄, PPAR, estrogen, progesterone and Testosterone

Route of Drug Administration

(1) Local Route:-

(A) Topical:- ◆ skin (medicated and non medicated formulation)

◆ Through Mucous Membrane

(1) Ocular (Eye)

(2) Intranasal (Nose)

(3) Otitic (Ear)

(4) GIT - Non absorbable drug like Neomycin, sucral fate, Mag hydroxide

- (5) Bronchi and Lungs
- (6) **Anal** - suppositories, ointment
- (7) Vaginal - pessaries
- (8) Urethra - vogies, jelly
- (B) Deeper tissue** - ♦ Intra thecal
 - ♦ Intra articular
 - ♦ Retro bulbur
- (C) Intra arterial** - for contrast media in Angiography

(2) Systemic :- Drug reaches in Blood circulation

- (a) Oral**
 - most convenient, painless
 - have first pass metabolism
 - show less Bioavailability
- (b) Sublingual** - Drug placed under the tongue
 - Ex. lipid soluble drug like- Nitroglycerin, clonidine, isoprenaline and Nefidipine
 - Avoid first pass metabolism
- (c) Buccal**
 - drug between gum and chick
 - used for lipid soluble drug
 - Ex. Lozenge
- (d) Transdermal**- for highly lipid soluble
 - Ex- Scopolamine, Nicotine and Nitroglycerin
- (e) Inhalational**- Drug for Asthma - Salbutamol, Ipratropium
- Anaesthesia - Nitrous oxide

Parental Route (Have More bioavailability)

- IM - Angle - 90°
 - Muscles- gluteous maximus, Deltoid, Retus femoris
- SC - Angle - 45°
 - Irritant drug can not be administered.

- (1) **Dermojet** - No Needle.
- (2) **Pellet Implantation** - solid pellet introduced by trocher and canula.
- (3) Non Biodegradable (Sialistic) and Biodegradable implant.

Intradermal (ID) - Angle - 15-17°

- Also called intra cutaneous
- Majorly for diagnostic purpose
- Ex. BCG

Intra oseus - Drug placed in Bone Morrow

Dose

Loading dose - Therapeutic dose administered at the begining of Treatment

- Have no time interval
- May be administered in higher concentration
- Loading dose always determine by Vd

Maintenance Dose - Therapeutic dose administered with a specific time interval

- Have time interval
- Depend on clearance

Potency -Amount of drug needed to produce the responses.

- Lower dose produce same response will be more potent
- Those require Large dose for same response will be Less potent

Effective Dose (ED₅₀) - Dose that produce 50 % (Half) response of its maximum.

- More ED₅₀ lower the potency

Lethal Dose (LD₅₀) - Dose that result 50 % death of animal after receiving.

- More LD₅₀, safer the drug

Therapeutic Index (TI) = $\frac{LD_{50}}{ED_{50}}$

-TI is a Measure of safety. Drug have More TI are safer where as Low TI of Drug show toxicity.

ADR (Adverse drug reaction/adverse effect)

Pharmacovigilance - Detection, Assesment, Prevention and under stading of Adverse effect.

(A) **Predictable ADR** - These are Dose related adverse effect.

- (1) **Side Effect** - Related to therapeutic dose.
- (2) **Secondary Effect** - Related to primary Mechanism of Drug - Ex. super infection.
- (3) **Toxic effect** - Related to over dose or prolong used of drug.
- (4) **Tolerance** - Related to prolong used.
- (5) **Photo toxicity**

(B) **Unpredictable ADR** - Least related to Dose

Allergy - Change in Immune system (I E),

Idiosyncrasy - change in genetic system

◆ National pharmacovigilance programme was started november 2004 under CDSCO

Placebo (Dummy drug)

- **Single Blind** - Clinician know, patient don't know
- **Double Blind** - Both Clinician and patient don't know about Drug

Orphan Drug

-Orphan drug act - 1983

-Drug that is used in rare disease or disorder called orphan drug

Ex. N-Acetylcysteine in PCM poisoning,

Defevefrone - in Thalacemia patient